FDA Eases Enforcement on Hemp CBD Products but Comprehensive Federal Regulation Still Lacking

The Food and Drug Administration (FDA) has taken a notable step by signaling enforcement discretion for certain hemp-derived CBD products, a move that highlights both progress and persistent gaps in the regulation of the burgeoning CBD market. According to Marijuana Moment, the FDA's decision allows qualifying orally administered CBD products to be treated under a supplement-style framework, emphasizing safety, labeling, and marketing standards reminiscent of those applied to dietary supplements. This change comes as millions of Americans incorporate CBD into their daily wellness routines, but the lack of comprehensive regulation continues to leave both consumers and businesses in a state of uncertainty

The FDA's approach stops short of providing full regulatory approval or designating CBD as Generally Recognized As Safe (GRAS). Instead, it outlines a selective enforcement policy that applies only under narrow conditions, such as supplement-style standards, absence of contamination, and distribution within a physician-directed, Medicare-related framework. "This is not full regulatory approval. It does not establish CBD as Generally Recognized As Safe (GRAS), nor does it create durable protections for the broader market," said Thomas Winstanley, executive vice president and general manager of Edibles.com. The policy, while pragmatic, leaves significant aspects of the broader consumer market unaddressed

Since the passage of the 2018 Farm Bill, hemp-derived products have rapidly grown into a multi-billion-dollar sector, expanding access to cannabinoids beyond the reach of state-regulated cannabis markets. This expansion has normalized THC and increased the acceptance of plant-based wellness alternatives, with consumers turning to CBD for sleep, stress management, and general well-being. However, the regulatory landscape remains fragmented, with federal agencies and states offering conflicting guidance and responsible operators competing with less scrupulous actors exploiting regulatory loopholes

Recent legislative changes have introduced further uncertainty, particularly with the narrowing of the federal definition of hemp, which could impact product eligibility and market stability. Winstanley cautioned, "Without a clear federal standard, we risk creating an outcome worse than the problem policymakers are trying to solve. Overly restrictive or unclear rules will not eliminate demand. They will simply redirect it, potentially toward unregulated or imported products that lack basic safety oversight." The risk extends to the domestic supply chain, where farmers, manufacturers, and retailers face potential disruption if comprehensive standards are not established

While the FDA's move reflects growing alignment within the executive branch and among lawmakers that a federal framework is necessary, it remains a stopgap rather than a solution. The agency's focus on safety and transparency is a positive development, but true progress will require Congressional action to establish consistent standards for manufacturing, labeling, distribution, and access. As Winstanley emphasized, "These products have the potential to reshape how Americans approach wellness by offering accessible, plant-based alternatives that complement traditional care, but realizing that potential will require more than enforcement discretion. It will require policy."

From the OG Lab newsroom perspective, the FDA's enforcement discretion is a meaningful but incomplete step toward stabilizing the U.S. hemp CBD market. The move signals growing recognition of the sector's legitimacy, but without robust federal legislation, the market remains vulnerable to regulatory shocks and consumer risk. Industry stakeholders should closely monitor legislative developments, as the next phase of regulation will determine the future landscape for both businesses and consumers